Reservoir host
Unconfirmed
Fruit bats are suspected but no host has been confirmed for this species.
Licensed vaccine
None
Ervebo® protects against Zaire virus only — a different Ebola species.
Targeted treatment
None
Monoclonal antibodies exist for Zaire virus, not for this species.
Case fatality
30.9%this outbreak
Historical Ebola species range from roughly 25% to 90% CFR.
What it is
Bundibugyo ebolavirus is one of six known species in the genus Orthoebolavirus, family Filoviridae. It was first identified in 2007 during an outbreak in Bundibugyo District, Uganda — the district it's named for.
It is a zoonotic disease: the virus normally circulates in wildlife and occasionally spills over into humans, after which it can spread from person to person.
Transmission
Initial infection follows contact with the blood or secretions of infected wildlife — bats or non-human primates. Human-to-human spread then occurs through direct contact with blood, secretions, organs, or other bodily fluids, and is amplified in healthcare and funeral settings.
Symptoms
Sudden fever, fatigue, muscle pain, headache, and sore throat, typically followed by vomiting, diarrhoea, rash, and signs of impaired kidney and liver function. Some patients develop internal and external bleeding.
FeverFatigueMuscle painVomitingDiarrhoeaBleeding (some cases)
Why this species is different
The 2014–16 West Africa epidemic and most Ebola vaccine research targeted Zaire ebolavirus. Bundibugyo virus is genetically distinct enough that those countermeasures don't reliably apply — which is why WHO reports no licensed vaccine or specific treatment for this outbreak. Care is limited to supportive treatment: fluids, symptom management, and treating complications early.
Sources · WHO Regional Office for Africa, Disease Outbreak News (2026-DON603) · Bundibugyo ebolavirus, peer-reviewed virology literature.